<p>在過去的 7 天裏，美國市場上漲了 3.1%，過去一年累計上漲了 27%，預計年收益增長為 16%。在如此強勁的市場環境中，擁有高內部持股的成長型公司尤其具有吸引力，因為這通常表明那些與業務運營和未來前景最接近的人士對公司的強烈信心。</p>
<h3>美國高內部持股的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>優信 (UXIN)</td>
<td>35.6%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>13%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>27.3%</td>
<td>42.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>11.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>13.2%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>20.7%</td>
<td>97.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.3%</td>
<td>21.6%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們篩選出的 203 只高內部持股的快速成長美國公司的完整名單。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>ASP Isotopes (ASPI)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ASP Isotopes Inc. 是一家處於開發階段的先進材料公司，專注於生產、分銷、營銷和銷售同位素，市值為 5.6405 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過兩個部門產生收入：建築服務，收入為 1818 萬美元，以及專業同位素及相關服務，貢獻 567 萬美元。</p>
<p><strong>內部持股：</strong> 13.5%</p>
<p><strong>收入增長預測：</strong> 年增長 49.4%。</p>
<p>ASP Isotopes 正在經歷顯著的收入增長，預計年增長率為 49.4%，超過美國市場平均水平。儘管過去經歷了股東稀釋和股價波動，該公司預計將在三年內實現盈利。最近的進展包括其 Renergen 氦氣項目的進展和核燃料生產的戰略合作伙伴關係。然而，仍面臨延遲提交 SEC 文件和預計 2025 年淨虧損 1.7509 億美元（收入 2385 萬美元）的重大挑戰。</p>
<ul>
<li>在我們的收益增長報告中更詳細地瞭解 ASP Isotopes 的潛力。</li>
<li>我們的 ASP Isotopes 估值報告分析表明，其股價可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 ASPI 收益和收入增長</p>
<h2>Eton Pharmaceuticals (ETON)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Eton Pharmaceuticals, Inc. 是一家制藥公司，開發和商業化罕見疾病的治療方案，市值為 7.1922 億美元。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其專注於開發和商業化處方藥產品的部門，收入為 7995 萬美元。</p>
<p><strong>內部持股：</strong> 15%</p>
<p><strong>收入增長預測：</strong> 年增長 29.8%。</p>
<p>Eton Pharmaceuticals 預計將實現顯著增長，收入預計年增長 29.8%，超過美國市場平均水平。最近獲得 FDA 對 DESMODA 的批准以及收購 HEMANGEOL 商業化權利增強了其產品組合。該公司預計 2026 年收入將超過 1.1 億美元，得益於戰略性許可交易和對超罕見疾病的關注。儘管 2025 年淨虧損 460 萬美元，Eton 計劃在三年內實現盈利。</p>
<ul>
<li>在這裏通過我們的全面分析師估計報告深入瞭解 Eton Pharmaceuticals 的複雜性。</li>
<li>我們的估值報告揭示了 Eton Pharmaceuticals 的股票可能以溢價交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 ETON 收益和收入增長</p>
<h2>FirstSun Capital Bancorp (FSUN)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> FirstSun Capital Bancorp 是 Sunflower Bank, National Association 的銀行控股公司，市值為 10.5 億美元，為美國中小型企業提供商業和消費者銀行及金融服務。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其銀行部門，收入為 3.226 億美元，另有 7656 萬美元來自抵押貸款業務，而公司部門則反映出 449 萬美元的虧損。</p>
<p><strong>內部持股：</strong> 37.1%</p>
<p><strong>收入增長預測：</strong> 年增長 31.9%。</p>
<p>FirstSun Capital Bancorp 正在經歷強勁增長，預計收益年增長 43.6%，超過美國市場平均水平。該公司以顯著折扣交易於其估計的公允價值，並相較於同行提供良好的相對價值。最近的董事會變動包括從 First Foundation Inc. 增加關鍵董事，以增強合併後的治理。儘管被多個指數剔除，FirstSun 的內部購買仍然積極，表明對其增長軌跡的信心。</p>
<ul>
<li>在這裏深入瞭解 FirstSun Capital Bancorp 的全面分析未來增長報告。</li>
<li>我們的估值報告揭示了 FirstSun Capital Bancorp 的股票可能以折扣交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 FSUN 收益和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>在這裏深入瞭解我們識別的 203 只高內部持股的快速成長美國公司。</li>
<li>想要探索一些替代方案？我們發現 11 只預計明年將支付超過 6% 股息收益的美國股票。查看完整名單，免費獲取。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

優信

ETON

FSUN

<p>美國市場在過去一週上漲了 3.1%，在過去一年中上漲了 27%，預計年收益增長將達到 16%。高內部持股的成長型公司被認為是有吸引力的投資。頂尖公司包括優信（內部持股 35.6%，收益增長 74.1%）和 Eton Pharmaceuticals（內部持股 15%，收益增長 29.8%）。ASP Isotopes 和 FirstSun Capital Bancorp 也顯示出強勁的增長潛力。文章強調了內部持股作為信心指標的重要性，並提供了對各公司財務預測和市場地位的見解</p>

<p>Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場上漲了 3.1%，過去一年累計上漲了 27%，預計年收益增長為 16%。在如此強勁的市場環境中，擁有高內部持股的成長型公司尤其具有吸引力，因為這通常表明那些與業務運營和未來前景最接近的人士對公司的強烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國高內部持股的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>35.6%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>13%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>27.3%</td>
<td>42.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>11.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>13.2%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>20.7%</td>
<td>97.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.3%</td>
<td>21.6%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>優信 (UXIN)</td>
<td>35.6%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>13%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>27.3%</td>
<td>42.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>11.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>13.2%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>20.7%</td>
<td>97.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.3%</td>
<td>21.6%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 203 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們篩選出的 203 只高內部持股的快速成長美國公司的完整名單。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>ASP Isotopes (ASPI)</h2>
<div class="lb-trans"><h2>ASP Isotopes (ASPI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ASP Isotopes Inc. is a development stage advanced materials company focused on producing, distributing, marketing, and selling isotopes with a market cap of $564.05 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> ASP Isotopes Inc. 是一家處於開發階段的先進材料公司，專注於生產、分銷、營銷和銷售同位素，市值為 5.6405 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from two main segments: Construction Services, which accounts for $18.18 million, and Specialist Isotopes and Related Services, contributing $5.67 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過兩個部門產生收入：建築服務，收入為 1818 萬美元，以及專業同位素及相關服務，貢獻 567 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 13.5%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 13.5%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 49.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年增長 49.4%。</p>
</div><p>ASP Isotopes is experiencing substantial revenue growth, with a forecast of 49.4% annually, surpassing the US market average. Despite past shareholder dilution and a volatile share price, the company is on track to become profitable in three years. Recent developments include advancements in its Renergen Helium Project and strategic partnerships for nuclear fuel production. However, challenges remain with delayed SEC filings and significant net losses reported for 2025 at US$175.09 million against revenues of US$23.85 million.</p>
<div class="lb-trans"><p>ASP Isotopes 正在經歷顯著的收入增長，預計年增長率為 49.4%，超過美國市場平均水平。儘管過去經歷了股東稀釋和股價波動，該公司預計將在三年內實現盈利。最近的進展包括其 Renergen 氦氣項目的進展和核燃料生產的戰略合作伙伴關係。然而，仍面臨延遲提交 SEC 文件和預計 2025 年淨虧損 1.7509 億美元（收入 2385 萬美元）的重大挑戰。</p>
</div><ul>
<li>Take a closer look at ASP Isotopes' potential here in our earnings growth report.</li>
<li>The analysis detailed in our ASP Isotopes valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的收益增長報告中更詳細地瞭解 ASP Isotopes 的潛力。</li>
<li>我們的 ASP Isotopes 估值報告分析表明，其股價可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth"/></p>
<p>ASPI Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 ASPI 收益和收入增長</p>
</div><h2>Eton Pharmaceuticals (ETON)</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals (ETON)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Eton Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes treatments for rare diseases, with a market cap of $719.22 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Eton Pharmaceuticals, Inc. 是一家制藥公司，開發和商業化罕見疾病的治療方案，市值為 7.1922 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its segment focused on developing and commercializing prescription drug products, which generated $79.95 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其專注於開發和商業化處方藥產品的部門，收入為 7995 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 15%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 15%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 29.8% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年增長 29.8%。</p>
</div><p>Eton Pharmaceuticals is poised for significant growth, with revenue expected to increase by 29.8% annually, outpacing the US market average. Recent FDA approval of DESMODA and the acquisition of HEMANGEOL commercialization rights bolster its product portfolio. The company anticipates 2026 revenues exceeding US$110 million, supported by strategic in-licensing deals and a focus on ultra-rare diseases. Despite a net loss of US$4.6 million in 2025, Eton aims for profitability within three years.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 預計將實現顯著增長，收入預計年增長 29.8%，超過美國市場平均水平。最近獲得 FDA 對 DESMODA 的批准以及收購 HEMANGEOL 商業化權利增強了其產品組合。該公司預計 2026 年收入將超過 1.1 億美元，得益於戰略性許可交易和對超罕見疾病的關注。儘管 2025 年淨虧損 460 萬美元，Eton 計劃在三年內實現盈利。</p>
</div><ul>
<li>Navigate through the intricacies of Eton Pharmaceuticals with our comprehensive analyst estimates report here.</li>
<li>Our valuation report unveils the possibility Eton Pharmaceuticals' shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏通過我們的全面分析師估計報告深入瞭解 Eton Pharmaceuticals 的複雜性。</li>
<li>我們的估值報告揭示了 Eton Pharmaceuticals 的股票可能以溢價交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth"/></p>
<p>ETON Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 ETON 收益和收入增長</p>
</div><h2>FirstSun Capital Bancorp (FSUN)</h2>
<div class="lb-trans"><h2>FirstSun Capital Bancorp (FSUN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> FirstSun Capital Bancorp, with a market cap of $1.05 billion, operates as the bank holding company for Sunflower Bank, National Association, offering commercial and consumer banking and financial services to small and medium-sized companies in the United States.</p>
<div class="lb-trans"><p><strong>概述：</strong> FirstSun Capital Bancorp 是 Sunflower Bank, National Association 的銀行控股公司，市值為 10.5 億美元，為美國中小型企業提供商業和消費者銀行及金融服務。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Banking segment, which accounts for $322.60 million, supplemented by $76.56 million from Mortgage Operations, while the Corporate segment reflects a loss of $4.49 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其銀行部門，收入為 3.226 億美元，另有 7656 萬美元來自抵押貸款業務，而公司部門則反映出 449 萬美元的虧損。</p>
</div><p><strong>Insider Ownership:</strong> 37.1%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 37.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 31.9% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年增長 31.9%。</p>
</div><p>FirstSun Capital Bancorp is experiencing robust growth, with earnings projected to rise 43.6% annually, surpassing the US market average. The company trades at a significant discount to its estimated fair value and offers good relative value compared to peers. Recent board changes include the addition of key directors from First Foundation Inc., enhancing governance post-merger. Despite being dropped from several indices, FirstSun's insider buying remains positive, indicating confidence in its growth trajectory.</p>
<div class="lb-trans"><p>FirstSun Capital Bancorp 正在經歷強勁增長，預計收益年增長 43.6%，超過美國市場平均水平。該公司以顯著折扣交易於其估計的公允價值，並相較於同行提供良好的相對價值。最近的董事會變動包括從 First Foundation Inc. 增加關鍵董事，以增強合併後的治理。儘管被多個指數剔除，FirstSun 的內部購買仍然積極，表明對其增長軌跡的信心。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of FirstSun Capital Bancorp.</li>
<li>Our valuation report unveils the possibility FirstSun Capital Bancorp's shares may be trading at a discount.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 FirstSun Capital Bancorp 的全面分析未來增長報告。</li>
<li>我們的估值報告揭示了 FirstSun Capital Bancorp 的股票可能以折扣交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth"/></p>
<p>FSUN Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 FSUN 收益和收入增長</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Dive into all 203 of the Fast Growing US Companies With High Insider Ownership we have identified here.</li>
<li>Want To Explore Some Alternatives? We've found 11 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解我們識別的 203 只高內部持股的快速成長美國公司。</li>
<li>想要探索一些替代方案？我們發現 11 只預計明年將支付超過 6% 股息收益的美國股票。查看完整名單，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

2026 年 4 月內部持股比例高的頂級成長公司